Psilocybin in Palliative Care: Research and Ethics

Psilocybin & End-of-Life

57-79% symptom reduction rate

A 14-study systematic review found 57-79% of palliative patients achieved at least 50% reduction in depression and anxiety after psilocybin treatment, with improvements lasting 6-8 months in most trials.

Lapid et al., Palliative & Supportive Care, 2025

8.8 points

mean demoralization reduction in first hospice-specific psilocybin RCT despite ongoing clinical decline (PATH trial, Beaussant 2026)

16 recommendations

from a 57-stakeholder forum on equitable palliative psilocybin access across 6 domains (Dorval 2025)

6-8 hours

session duration requirement that makes psilocybin incompatible with most hospice settings as currently designed

Lapid et al., Palliative & Supportive Care, 2025

View as image ↗

The evidence for psilocybin in palliative care is now substantial. A 2025 systematic review covering 14 studies found that 57-79% of patients with serious illness achieved at least a 50% reduction in depression and anxiety symptoms, with those improvements lasting 6-8 months in most trials.^[1] A 2025 network meta-analysis confirmed that psilocybin functions as a rapid-acting treatment for cancer-related distress, comparing favorably to other available options.^[3]

The problem is not the evidence. The problem is that virtually no dying person can actually access this treatment.

Most palliative patients seeking psilocybin face a wall: it remains federally illegal in the US, sessions last 6-8 hours (incompatible with most hospice settings), therapist training requirements are formalized in only a handful of jurisdictions, and costs run into the thousands of dollars per session with no insurance coverage. The evidence has outpaced every supporting structure needed to deliver it.

This article covers the full picture: what the research actually shows, why access remains nearly impossible, the unique ethical challenges specific to dying patients, and what the field now recommends to change it. For a broader look at what psilocybin does for existential anxiety in cancer patients, see the complete guide to psilocybin for cancer patients.

What 14 Studies and the Latest Meta-Analyses Actually Show

Lapid and colleagues at the Mayo Clinic published a 2025 systematic review covering 14 studies across three formats: three randomized controlled trials, five open-label trials, and five qualitative investigations.^[1] Their summary: psilocybin consistently reduced depression, anxiety, and existential distress in patients with serious illness. Between 57% and 79% of participants achieved at least 50% reduction in their symptom burden. Those improvements held at 6-8 months in most trials.

A 2025 network meta-analysis by Swieczkowski placed psilocybin's performance in comparative context.^[3] When evaluated against other available treatments for cancer-related depression and anxiety, psilocybin consistently ranked as a rapid-acting intervention with favorable positioning relative to both pharmacological options and other psychedelic approaches.

A 2026 narrative review by Magnani and colleagues offers a framing shift worth understanding before going further.^[11] The field has historically described the problem as "anxiety and depression." Magnani argues the more precise label is "psycho-existential distress": a condition that includes the psychological symptoms but also the loss of meaning, the collapse of the sense of self, and the confrontation with finitude that standard psychiatric categories don't fully capture. This matters because it clarifies what psilocybin is actually treating. The relevant outcomes aren't limited to anxiety scores. They include whether a patient can find meaning in their remaining life.

For deeper coverage of what the foundational 2016 trials found, and how the long-term follow-up data changed the story, the NYU and Hopkins trial results covers the evidence from both research teams in detail.

The PATH Trial: The First Psilocybin Study Conducted in an Actual Hospice

In 2026, Beaussant and colleagues published results from the PATH trial (Psilocybin Assisted Therapy for Hospice).^[2] This was the first randomized controlled trial of psilocybin conducted specifically in hospice patients, and the distinction matters.

Previous trials enrolled cancer patients who were seriously ill but not necessarily at the hospice stage. The PATH trial enrolled nine patients who were already in hospice, already in clinical decline. The primary outcome was demoralization: the specific collapse of meaning, helplessness, and sense that the future holds nothing that defines the late-stage experience. For a dedicated examination of what demoralization syndrome is and why it requires different framing than depression, see psilocybin and demoralization.

Within three weeks of a single psilocybin session, the demoralization score dropped by 8.8 points on average (p=0.0196).^[2]

The finding that makes this unusual is the context. These patients were still declining clinically. Their bodies were not improving. Their disease progression had not reversed. And yet their psychological and existential distress measurably improved. Improvement while deteriorating is a different kind of evidence than improvement in a patient whose medical situation is stabilizing.

No serious adverse events were reported. Session themes documented by therapists included grief and peace. Patients described processing their approaching death rather than avoiding it.

The sample size of nine is small, and the results should be read as preliminary. But the proof-of-concept is significant: a hospice setting, a terminally ill population, a primary endpoint of existential distress, positive results, and no serious safety signals.

Why Most Dying Patients Still Can't Get This Treatment

Whinkin and colleagues published a 2023 clinical update on psilocybin specifically for geriatric and end-of-life populations.^[4] Their summary of barriers falls into four categories: legal, financial, logistical, and population-specific.

The legal barrier is straightforward in most places: psilocybin remains Schedule I under US federal law. Oregon and Colorado have created regulated access programs, but federal employment protections, insurance coverage, and VA services remain off-limits everywhere. Patients in most states have no legal path at all.

The financial barrier compounds the legal one. A single properly conducted psilocybin session with trained guides costs $1,000-$3,000 or more, depending on jurisdiction and setting. No health insurance covers it. For a patient exhausting their savings on oncology care or managing hospice expenses on a fixed income, this cost is prohibitive.

The logistical barrier is specific to the treatment format. Psilocybin sessions require 6-8 hours with two trained facilitators present throughout. Hospice facilities are not staffed or designed for this. Patients who are bedridden or physically fragile have additional constraints. The session structure that functions in a research clinic does not map cleanly onto a hospice room.

The population-specific barrier is less discussed. Older adults with mild cognitive impairment, complex medication regimens, or cardiovascular conditions may face additional contraindications or monitoring requirements.^[4] The clinical trial populations have generally been healthier than the average hospice patient.

Umbacia and colleagues (2025) describe the practical gap between the research environment and clinical adoption as one of the field's most pressing implementation problems.^[12] The evidence base exists. The delivery infrastructure does not.

The Ethical Challenges Specific to Dying Patients

Psychedelic therapy raises ethical questions in any context. In palliative care, those questions become more acute because the patient population is uniquely vulnerable. Caporuscio and colleagues published a 2025 systematic scoping review of ethical issues in psychedelic-assisted treatments.^[5] Five challenges are particularly relevant to end-of-life settings:

Informed consent under cognitive impairment. End-of-life patients often experience the desire for hastened death, a psychological state that can compromise decision-making. A patient who is desperate, frightened, or mildly cognitively impaired may consent to psilocybin without fully processing the risks. The standard clinical consent process was not designed for this population.

Power imbalance in the therapeutic relationship. Psilocybin sessions generate intense trust and vulnerability. Patients in desperate circumstances are not in equal power positions relative to their therapists. This dynamic is not unique to dying patients, but it is amplified. A patient who credits their session with reducing their fear of death may feel unable to critique their therapist or report concerns.

Access inequity across race and income. The trial populations to date have been disproportionately white and educated. Legal access in states like Oregon favors patients with financial resources and geographic flexibility. A treatment that works but is available only to privileged populations raises serious questions about who benefits from the evidence base.^[5]

Setting and staffing requirements. The 6-8 hour session requirement does not fit hospice infrastructure. Who supervises the session? What happens if a patient has a medical emergency during the acute experience? These are practical ethics questions, not hypothetical ones.

Regulatory patchwork. Even in states where psilocybin is legal, the rules vary enough that a patient who moves into hospice care may lose access entirely. Federal employment consequences and insurance exclusions create downstream harms for patients and families attempting to navigate the system.

For context on how these ethical challenges compare to psychedelic therapy ethics more broadly, ethics in psychedelic therapy covers the full landscape beyond end-of-life specifically.

What 57 Experts Agreed On: A 16-Point Roadmap for Access

Dorval and colleagues organized the P3A forum in 2025, convening 57 stakeholders: patients, family members, clinicians, researchers, policymakers, and representatives from Indigenous communities.^[6] The goal was to produce concrete recommendations rather than abstract positions.

The forum produced 16 recommendations organized across 6 domains.

Patient eligibility and equity. Eligibility criteria should be designed to actively include marginalized groups who are underrepresented in trials. Financial assistance programs should be built into access frameworks from the start, not added as an afterthought.

Regulatory framework and patient autonomy. Regulatory structures should preserve patient autonomy, including the right to access evidence-based treatments for end-of-life distress when other options have been exhausted.

Logistical and organizational aspects. Session delivery needs to be redesigned for palliative settings. This includes mobile facilitator teams who can work in patients' homes, flexible timing protocols, and procedures adapted for patients with physical limitations or compromised stamina.

Professional training. Facilitators working with dying patients need specialized training in grief, existential distress, and end-of-life psychology. General psychedelic facilitation training is not sufficient for this population.

Public awareness. Stigma surrounding both psychedelics and death itself creates barriers before patients can even research their options. Public education is part of the access infrastructure, not a separate concern.

Research priorities. Future trials should prioritize real-world hospice settings, cognitively impaired populations, and underrepresented groups. Most existing evidence comes from relatively healthy, white, educated cancer patients who are not representative of the people most likely to die in existential distress.^[6]

The forum's core conclusion: access to psilocybin in palliative care is not only a regulatory problem. It is a justice problem.

Can Group Therapy Make Psilocybin Accessible at Scale?

The standard psilocybin session format, one patient and two guides over 6-8 hours, is expensive at every level of the system. Agrawal and colleagues (2024) tested whether a group therapy format could work without eliminating the treatment's benefits.^[7]

Their trial enrolled 30 cancer patients with a major depressive disorder diagnosis. Participants received psilocybin-assisted group therapy rather than individual sessions. The results demonstrated feasibility and clinically meaningful depression improvement. Group format did not undermine the treatment effects, and it substantially changed the economics: one or two facilitators working with multiple patients in a single session is a different cost structure than one-on-one care.

The hospice context adds a second practical argument for group formats. Dying patients often share questions that are genuinely collective: how to prepare, how to be with uncertainty, what happens to the things they care about. A group that shares an advanced illness diagnosis may provide peer support alongside the pharmacological effects. This remains a hypothesis rather than a finding, but it represents a meaningful design consideration for palliative programs.

A related question is whether multiple sessions are even feasible in hospice. Palliative patients may not survive to complete a multi-session protocol. For a review of what the evidence shows about single versus multiple sessions and long-term effects, the session-count question addresses this directly. For patients who may not have weeks or months to spare, the case for a single-session model is particularly relevant.

What Patients Actually Say: Stigma, Desperation, and the People Most Ready to Try It

D'Angelo and colleagues (2025) interviewed 15 cancer patients about their perspectives on psilocybin-assisted therapy.^[8] Analysis of those interviews produced four themes.

The first was cautious optimism: most patients were open to psilocybin but held back by lack of information and uncertainty about what the experience would involve. The second was cultural stigma: decades of anti-drug messaging make it difficult to frame psilocybin as medicine. Many patients described avoiding the topic with their oncologists, worried about being judged or flagged in their records.

The third was practical barriers: cost, legality, and finding a trustworthy provider. The fourth, and perhaps the most important: existential distress itself drove openness.

Patients in advanced disease were more open to psilocybin than earlier-stage patients. When conventional medicine has nothing more to offer for existential despair, the calculation changes. The question becomes less "should I try this?" and more "how do I actually access it?"

Khan and colleagues (2026) provide some of the most granular patient-generated data in the literature on this topic.^[9] Their interpretative phenomenological study followed 7 UK women with cancer-related existential distress through psilocybin experiences. Three central themes emerged in the patients' own language: reconciliation with death, acknowledgment of cancer's place in their life, and confidence in the face of potential recurrence.

The phrase "cancer found its place" captures something that clinical scales don't record. The psilocybin session did not remove the cancer or dissolve the fear. It changed the relationship. Cancer became something that had a place in the patient's life story, rather than a force that had demolished it.

For a detailed examination of this process and what the research shows about how psilocybin changes the relationship with mortality more broadly, how psilocybin changes the relationship with mortality explores both the mechanism and the patient experience in depth. For patients asking specifically about meaning and how the evidence describes its restoration, psilocybin and meaning-making at end of life focuses on that dimension.

Oregon as the Real-World Experiment: What Early Access Is Revealing

Oregon became the first US state to legalize regulated psilocybin access for adults in 2020, and licensed service centers began operating in 2023. Bellman's 2024 review examined the post-approval landscape specifically for cancer patients seeking psilocybin following Oregon's rollout.^[10]

The findings illustrate both the possibility and the persistent gaps. Patients in Oregon can now legally access psilocybin services without a medical diagnosis or prescription. For cancer patients seeking palliative support, this opens a path that did not previously exist. But three problems have emerged early.

Access disparities by race and income have appeared immediately. The costs of Oregon's licensed service centers, combined with the requirement to be physically present in Oregon, mean the patients who benefit are disproportionately white, educated, and financially stable. The people who most need access are the least likely to have it.

Insurance coverage remains entirely absent. Oregon's psilocybin services are not covered by any health insurance. Medicaid patients cannot access them. Medicare patients cannot access them. The financial barrier that predated legalization has not been solved by legalization.

The clinical-legal gap persists. A cancer patient in Oregon can legally receive psilocybin at a service center. But their oncologist, operating under federal rules and hospital policy, typically cannot be involved in that care. The existential support a patient receives is disconnected from the medical team managing their disease.

Oregon represents the best-case scenario available in the US today. And it is still far from what the evidence says is possible. For a closer look at how quality of life specifically changes in terminal cancer patients across the trial data, psilocybin and quality of life in terminal cancer patients draws from the same evidence base.

The Bottom Line

Psilocybin has now been tested in 14 studies of palliative patients, and 57-79% of participants achieve meaningful symptom reduction that lasts months. The first hospice-specific trial showed improvement in dying patients who were still clinically declining. The barriers to access, legal, financial, logistical, and ethical, are not hypothetical: they are the reason most dying people who could benefit from this treatment cannot get it. A 57-stakeholder forum has now produced a detailed roadmap for what equitable access would require. The gap between what the research shows and what patients can actually access is where this field is working.

Frequently Asked Questions

Is psilocybin available in palliative care?

In most places, no. Psilocybin is federally illegal in the US and restricted in most countries, which means palliative patients cannot access it through standard medical care. Oregon and Colorado have legal psilocybin service programs that adults can access without a prescription, but costs, geographic requirements, and the absence of insurance coverage make these options inaccessible for most dying patients. A handful of clinical trials are enrolling palliative patients, which represents one of the few pathways to legal access outside of those two states.

What are the ethical concerns with psilocybin for dying patients?

Five stand out as specific to the end-of-life context. First, informed consent is complicated when patients are cognitively impaired or in states of desperation that can compromise decision-making. Second, the intense trust created during a psilocybin session creates power imbalances that are amplified in vulnerable populations. Third, access is deeply inequitable by race and income. Fourth, the 6-8 hour session requirement does not fit hospice settings or the physical capacities of many dying patients. Fifth, regulatory variation means a patient who qualifies under one jurisdiction's rules may lose access if they transfer to a different care setting. Caporuscio et al. (2025) provide the most comprehensive scoping review of these specific concerns.

Who can receive psilocybin in hospice?

Currently, the honest answer is almost no one through formal channels. The PATH trial (Beaussant 2026) enrolled nine terminally ill hospice patients under a research protocol and found significant benefit. But research protocols are not the same as clinical access. Outside of clinical trials, hospice patients in Oregon may be able to access licensed psilocybin service centers independently of their hospice program, though the costs and logistics create substantial barriers. The Dorval 2025 roadmap documents what would need to change for hospice to become a viable setting for psilocybin-assisted care.

Can terminally ill patients access psilocybin legally?

Yes, in limited circumstances. Oregon and Colorado both allow adults to access psilocybin legally without a diagnosis or prescription at licensed service centers. Some terminally ill patients have accessed psilocybin through these routes. Clinical trials enrolling palliative patients also offer legal access within a research framework. In countries with compassionate use frameworks, individual applications may be possible. The legal access that exists is patchy, expensive, and geographically constrained. Bellman (2024) reviews what legal access has actually looked like for cancer patients since Oregon's service centers opened.

What does current research say about psilocybin for dying patients?

The evidence is consistent and growing. A 2025 systematic review of 14 studies found 57-79% of patients achieving ≥50% symptom reduction in depression and anxiety, with improvements lasting 6-8 months in most trials (Lapid et al.). A 2025 network meta-analysis identified psilocybin as a rapid-acting option that compares favorably to other available treatments (Swieczkowski et al.). The first hospice-specific RCT, the PATH trial, found an 8.8-point mean reduction in demoralization in patients who were still in clinical decline (Beaussant et al., 2026). The evidence is primarily from small trials with non-representative samples. Results have been consistent across teams and methods. Access remains the dominant unresolved problem.

Sources & References

1. 1RTHM-02122·Lapid, Maria I et al. (2025). “Evaluating the effectiveness of psilocybin in alleviating distress among cancer patients: A systematic review..” Palliative & supportive care.Study breakdown →PubMed →↩
2. 2RTHM-02223·Beaussant, Yvan et al. (2026). “Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy..” BMJ supportive & palliative care.Study breakdown →PubMed →↩
3. 3RTHM-02190·Swieczkowski, Damian et al. (2025). “Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis..” International journal of psychiatry in medicine.Study breakdown →PubMed →↩
4. 4RTHM-01818·Whinkin, Emily et al. (2023). “Psilocybin in Palliative Care: An Update..” Current geriatrics reports.Study breakdown →PubMed →↩
5. 5RTHM-02065·Caporuscio, Chiara et al. (2025). “Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review..” Psychological medicine.Study breakdown →PubMed →↩
6. 6RTHM-02076·Dorval, Michel et al. (2025). “Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care..” Palliative medicine reports.Study breakdown →PubMed →↩
7. 7RTHM-01846·Agrawal, Manish et al. (2024). “Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder..” Cancer.Study breakdown →PubMed →↩
8. 8RTHM-02072·D M Schuman, Haley et al. (2025). “"Facing Death. . . Now, That's a Serious Thing to Confront" A Qualitative Analysis of Patient Perspectives on Psychedelic-Assisted Therapy for Cancer-Related Psychosocial Symptoms..” Integrative cancer therapies.Study breakdown →PubMed →↩
9. 9RTHM-02235·Khan, Zaynab et al. (2026). “Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis..” Qualitative health research.Study breakdown →PubMed →↩
10. 10RTHM-01858·Bellman, Val (2024). “Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon..” Cancers.Study breakdown →PubMed →↩
11. 11RTHM-02236·Magnani, Luca et al. (2026). “Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review..” BMJ supportive & palliative care.Study breakdown →PubMed →↩
12. 12RTHM-02196·Umbacia, Maria-Alejandra et al. (2025). “Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being..” Expert opinion on emerging drugs.Study breakdown →PubMed →↩